Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasms 9Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 17fludarabine 16fludarabine phosphate 11venetoclax 9Azacitidine 9Rituximab 8Nivolumab 7Melphalan 7Tacrolimus 6Cytarabine 6Specimen Handling 5Sirolimus 5Ipilimumab 5Clofarabine 5CTLA-4 Antigen 5Antilymphocyte Serum 5belinostat 4aldesleukin 4Thiotepa 4Standard of Care 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Busulfan 4Bortezomib 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Neoplasms × SNX-5422 × Clear all
NCT01635712 2017-04-26

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

Esanex Inc.

Phase 1 Completed
10 enrolled
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT00595686 2012-05-17

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Esanex Inc.

Phase 1 Completed
25 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡